Literature DB >> 25734289

How concerns for bisphosphonate-induced osteonecrosis of the jaw affect clinical practice among dentists: a study from the South Texas Oral Health Network.

Cara B Gonzales, Veronica Young, Norma S Ketchum, Jamie Bone, Thomas W Oates, Rahma Mungia.   

Abstract

Bisphosphonate-induced osteonecrosis of the jaw (BONJ) represents a growing concern for dentists and patients in that it may alter clinical care. This study assessed the knowledge and perceptions of practicing dentists in relation to the risk of BONJ and how their knowledge and perceptions influence their decisions when developing treatment plans. For this study, a sample of dentists (n = 93) in South Texas completed a 38-item survey about BONJ knowledge and perception and their current clinical practices for patients undergoing bisphosphonate therapy. Knowledge score groupings reflected differences between low knowledge and high knowledge dentists in terms of their behavior concerning medical history, alternative treatments offered, and routine blood testing for patients on bisphosphonate therapy.

Entities:  

Keywords:  bisphosphonate osteonecrosis of the jaw; dental care

Mesh:

Year:  2015        PMID: 25734289      PMCID: PMC4426384     

Source DB:  PubMed          Journal:  Gen Dent        ISSN: 0363-6771


  38 in total

1.  Bisphosphonates--what the dentist needs to know: practical considerations.

Authors:  John E Fantasia
Journal:  J Oral Maxillofac Surg       Date:  2009-05       Impact factor: 1.895

Review 2.  Bisphosphonate and nonbisphosphonate-associated osteonecrosis of the jaw: a review.

Authors:  Soulafa A Almazrooa; Sook-Bin Woo
Journal:  J Am Dent Assoc       Date:  2009-07       Impact factor: 3.634

3.  Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia.

Authors:  Tony Mavrokokki; Andrew Cheng; Brien Stein; Alastair Goss
Journal:  J Oral Maxillofac Surg       Date:  2007-03       Impact factor: 1.895

4.  Prolonged efficacy of a single dose of the bisphosphonate zoledronic acid.

Authors:  Janet E Brown; Susan P Ellis; James E Lester; Sandra Gutcher; Tina Khanna; Om-Prakesh Purohit; Eugene McCloskey; Robert E Coleman
Journal:  Clin Cancer Res       Date:  2007-09-15       Impact factor: 12.531

Review 5.  Biophosphonate-related osteonecrosis of the jaws.

Authors:  Salvatore L Ruggiero; Sook-Bin Woo
Journal:  Dent Clin North Am       Date:  2008-01

6.  Zoledronate, smoking, and obesity are strong risk factors for osteonecrosis of the jaw: a case-control study.

Authors:  John H Wessel; Thomas B Dodson; Athanasios I Zavras
Journal:  J Oral Maxillofac Surg       Date:  2008-04       Impact factor: 1.895

7.  Bisphosphonate use and the risk of adverse jaw outcomes: a medical claims study of 714,217 people.

Authors:  Vassiliki M Cartsos; Shao Zhu; Athanasios I Zavras
Journal:  J Am Dent Assoc       Date:  2008-01       Impact factor: 3.634

8.  Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment.

Authors:  Robert E Marx; Joseph E Cillo; Juan J Ulloa
Journal:  J Oral Maxillofac Surg       Date:  2007-12       Impact factor: 1.895

9.  Oral bisphosphonates as a cause of bisphosphonate-related osteonecrosis of the jaws: clinical findings, assessment of risks, and preventive strategies.

Authors:  Leon A Assael
Journal:  J Oral Maxillofac Surg       Date:  2009-05       Impact factor: 1.895

10.  Clinical, radiographic, and biochemical characterization of multiple myeloma patients with osteonecrosis of the jaw.

Authors:  Noopur Raje; Sook-Bin Woo; Karen Hande; Jeffrey T Yap; Paul G Richardson; Sonia Vallet; Nathaniel Treister; Teru Hideshima; Niall Sheehy; Shweta Chhetri; Brendan Connell; Wanling Xie; Yu-Tzu Tai; Agnieszka Szot-Barnes; Mei Tian; Robert L Schlossman; Edie Weller; Nikhil C Munshi; Annick D Van Den Abbeele; Kenneth C Anderson
Journal:  Clin Cancer Res       Date:  2008-04-15       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.